Andrzej Jakubowiak, who is leading the trial, says four patients have been on the treatment long enough to be evaluated, and three of them have already been taken off other drugs and appear clinically stable which for advanced myeloma is an unusually good success rate.
ECONOMIST: Cancer therapy